Study (reference and country) | Cell type | ATRA treatment | miRNAs upregulated | miRNAs downregulated |
---|---|---|---|---|
Weiss et al. (2009) [51] Germany | PaTu8988-S and PaTu8988- | 1 μmol/L for 72 h | miR-10a | – |
Xia et al. (2009) [52] China | U343 and U251 | 1 μmol/L for 48 h | – | miR-125b |
Chen et al. [53] (2014) Taiwan | U87 MG | 10, 20, 40, and 60 μmol/L for 72 h | 13; miR-302b, miR-302a, miR-302d, miR-30a, miR-146a, miR-224, miR-135a, miR-137, miR-212, miR-628-3p, miR-200c, miR-146b-5p and miR-136; most significant: miR-302b | 15; miR-19a, miR-19b, miR-551b, miR-101, miR-301a, miR-199b-5p, miR-455-5p, miR-565, miR-107, miR-216a, miR-32, miR-33a, miR-17-5p, miR-497 and miR-210; most significant: miR-19a |
Chen et al. [54] (2014) China | NT2/D1 | 10 μmol/L for 21 days | – | miR-134 |
Liu et al. [55] (2018) China | HCT116 | 10, 20, 40, and 60 μmol/L for 24 h | miR-3666 | – |